Form 4: Neuronetics Director Sasha Cucuz Reports Acquisition of 30,000 Restricted Stock Units

Neuronetics, Inc. Director Sasha Cucuz has reported the acquisition of 30,000 restricted stock units (RSUs) on May 22, 2025, as part of a compensation award.

Summary

• Sasha Cucuz, a Director of Neuronetics, Inc. (STIM), acquired 30,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on May 22, 2025.
• These RSUs are scheduled to vest on the earlier of May 22, 2026, or the Reporting Person's Board-approved separation of service, contingent on continuous service.
• Each RSU represents a contingent right to receive one share of Neuronetics' common stock.
• Following this transaction, Sasha Cucuz directly beneficially owns 1,506,388 shares of Common Stock.
• Additionally, Sasha Cucuz indirectly beneficially owns 2,042 shares through Greybrook Realty Partners Inc. and 516,084 shares through Greybrook Health Inc., while disclaiming beneficial ownership except for pecuniary interest.

Sentiment

Score: 7

Explanation: The acquisition of Restricted Stock Units by a director is generally a positive signal, indicating alignment of interests and retention of key personnel. It's a standard compensation practice and doesn't suggest any immediate negative operational or financial issues for the company.

Positives

• The award of 30,000 Restricted Stock Units (RSUs) to Director Sasha Cucuz aligns management and director interests with shareholder value.
• RSUs are a common form of equity compensation, often used to retain key personnel and incentivize long-term performance.

Negatives

• No specific negative information is present in this Form 4 filing.

Risks

• The vesting of the 30,000 Restricted Stock Units (RSUs) is subject to Sasha Cucuz's continuous service with Neuronetics, Inc. until May 22, 2026, or earlier Board-approved separation.

Future Outlook

The vesting schedule for the 30,000 Restricted Stock Units (RSUs) indicates a future milestone for Director Sasha Cucuz's equity compensation, contingent on continuous service until May 22, 2026, or an earlier Board-approved separation.

Management Comments

• "Represents a restricted stock unit ('RSU') award that vests on the earlier of (a) May 22, 2026 or (b) the Reporting Person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the Reporting Person through such date."
• "Each RSU represents a contingent right to receive one share of the Issuer's common stock."
• "The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."

Industry Context

This Form 4 filing reflects a standard practice of equity compensation for directors in publicly traded companies, particularly in the medical device or healthcare technology sector where Neuronetics operates. Such awards are designed to align the interests of directors with long-term shareholder value and retain experienced leadership.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common compensation practice across various industries, including medical technology, aligning director incentives with company performance and shareholder returns.
• While specific RSU grant sizes vary widely based on company size, director responsibilities, and overall compensation philosophy, a grant of 30,000 units for a director at a company like Neuronetics (a medical device company) is within typical ranges for non-executive directors, especially if it's an annual or significant one-time award.
• Companies such as Medtronic (MDT), Boston Scientific (BSX), or smaller medical device firms often utilize similar equity-based compensation structures for their board members to foster long-term commitment.

Related Party Transactions

• Sasha Cucuz indirectly beneficially owns shares through Greybrook Realty Partners Inc. and Greybrook Health Inc., entities with which he likely has a relationship, though he disclaims beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's interests with long-term shareholder value, potentially leading to more focused governance and strategic decisions aimed at increasing stock price.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The 30,000 Restricted Stock Units (RSUs) are expected to vest on May 22, 2026, or earlier upon Board-approved separation, subject to continuous service.

Key Dates

Recommendation

Keywords

Neuronetics, STIM, Form 4, Sasha Cucuz, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Award, Beneficial Ownership